Nightingale Health is a global health technology company dedicated to transforming preventive care through innovative blood-testing services. By providing comprehensive health insights, it enables individuals to identify disease risks and assess the impact of lifestyle changes that standard lab tests may overlook. The company's Health Data Platform connects healthcare providers with the preventative health needs of individuals, fostering informed decision-making and encouraging proactive health management. Nightingale Health's approach emphasizes the importance of maintaining health rather than merely addressing illnesses, ultimately contributing to scientific advancements and promoting positive lifestyle changes among users.
My Nightingale develops and operates pre-symptomatic measures using NMR device to analyse blood components and provide solutions.
Negen Oy
Acquisition in 2022
Negen is a genetic testing and analysis technology company. The company offers genetic tests that are designed to show genetic risks for certain diseases and health problems such as type 2 diabetes and coronary heart disease.
Yolife
Acquisition in 2021
Yolife GmbH, founded in 2017 and based in Berlin, Germany, offers a mobile application focused on enhancing health through lifestyle changes, professional consultations, and medical therapies. The application is available on both the App Store and Google Play. Designed to help individuals add healthy years to their lives, Yolife’s app leverages insights from over 300 scientific studies to provide evidence-based lifestyle suggestions. It features an AI-driven approach that crafts personalized action plans for users, guiding them in fitness, nutrition, and wellness. Users can earn rewards for adhering to recommended diets, which also unlock deals from health-related products and services, thereby promoting overall health and well-being.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.